Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

Heat shock protein (HSP)90 inhibitors have shown significant anti-tumor activities in preclinical settings in both solid and hematological tumors. We previously reported that the novel, orally available HSP90α/β inhibitor TAS-116 shows significant anti-MM activities. In this study, we further examin...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Rikio, Kikuchi, Shohei, Harada, Takeshi, Mimura, Naoya, Minami, Jiro, Ohguchi, Hiroto, Yoshida, Yasuhiro, Sagawa, Morihiko, Gorgun, Gullu, Cirstea, Diana, Cottini, Francesca, Jakubikova, Jana, Tai, Yu-Tzu, Chauhan, Dharminder, Richardson, Paul G., Munshi, Nikhil, Ando, Kiyoshi, Utsugi, Teruhiro, Hideshima, Teru, Anderson, Kenneth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667922/
https://www.ncbi.nlm.nih.gov/pubmed/26630652
http://dx.doi.org/10.1371/journal.pone.0143847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667922/
https://www.ncbi.nlm.nih.gov/pubmed/26630652
http://dx.doi.org/10.1371/journal.pone.0143847

Ejemplares similares